References

Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women

10.1186/bcr1672 · 2007 · External reference

Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis

10.1200/jco.2006.09.2106 · 2007 · External reference

Time trends in systemic adjuvant treatment for node-negative breast cancer

10.1200/jco.1999.17.5.1458 · 1999 · External reference

Individual patient- versus literature-based meta-analysis of survival data: time to event and event rate at a particular time can make a difference, an example based on head and neck cancer

10.1016/s0197-2456(01)00152-0 · 2001 · External reference

Differences in management of older women influence breast cancer survival: results from a population-based database in Sweden

10.1371/journal.pmed.0030025 · 2006 · External reference

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer

10.1200/jco.1999.17.2.485 · 1999 · External reference

Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients

10.1002/1097-0142(20011001)92:7<1759::aid-cncr1691>3.0.co;2-a · 2001 · External reference

Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy

10.1093/annonc/mdg346 · 2003 · External reference

Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer

10.1016/j.ejca.2003.11.007 · 2004 · External reference

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

10.1200/jco.2005.05.098 · 2005 · External reference

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

10.1200/jco.2007.12.6557 · 2007 · External reference

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

10.1007/s10549-010-0901-4 · 2010 · External reference

A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC)

2007 · External reference

Unresolved reference

2001 · External reference

Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women

10.1200/jco.2005.02.167 · 2005 · External reference

Capecitabine monotherapy for elderly patients with metastatic breast cancer

10.1200/jco.2004.22.14_suppl.797 · 2004 · External reference

Phase II study of capecitabine (X) as single agent in elderly patients (p) with metastatic breast cancer (MBC): final results

10.1200/jco.2006.24.18_suppl.10709 · 2006 · External reference

Capecitabine (X) in elderly patients (pts) with hormone-refractory metastatic breast cancer (MBC)

10.1200/jco.2007.25.18_suppl.1080 · 2007 · External reference

Retrospective analysis of chemotherapy choices and overall survival according to treatment in 96 patients >=75years old with metastatic breast cancer

10.1016/s1359-6349(08)70731-6 · 2008 · External reference

Randomized, open-label, phase II trial of oral capecitabine (Xeloda(R)) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer

10.1023/a:1012281104865 · 2001 · External reference

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

10.1200/jco.2002.09.002 · 2002 · External reference

(OS) in patients with metastatic breast cancer (MBC) treated with capecitabine [abstract 1097]

2009 · External reference

Docetaxel plus epirubicin versus docetaxel plus capecitabine as first line treatment in patients with advanced breast cancer. Final results of a multicenter phase III trial (abstract 136O)

2008 · External reference

Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer

10.1200/jco.2007.15.8485 · 2009 · External reference

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer

10.1200/jco.2005.05.1383 · 2006 · External reference

Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer

10.1038/sj.bjc.6601784 · 2004 · External reference

Epirubicin/paclitaxel (EP) vs. capecitabine/paclitaxel (XP) in first-line metastatic breast cancer (MBC): a prospective, randomized multicentre phase III study of the AGO breast cancer study group

10.1200/jco.2006.24.18_suppl.517 · 2006 · External reference

Capecitabine and vinorelbine in metastatic breast cancer

10.1016/j.ejca.2009.04.031 · 2009 · External reference

Capecitabine (C) and vinorelbine (V) in elderly patients (pts) with metastatic breast cancer (MBC) as first line treatment: a prospective multicentre phase II study of the NOGGO breast cancer study group

2006 · External reference

Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65years) with metastatic breast cancer. A phase II trial (SAKK 25/99)

10.1159/000127414 · 2007 · External reference

Capecitabine and vinorelbine in elderly patients (> or =65years) with metastatic breast cancer: a phase I trial (SAKK 25/99)

10.1093/annonc/mdh467 · 2004 · External reference

Dose-escalated vinorelbine-capecitabine in elderly metastatic breast cancer patients. A SICOG phase II study (abstract 155P)

2006 · External reference

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03–05 study

10.1200/jco.2008.19.6618 · 2009 · External reference

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

10.1007/s10549-007-9885-0 · 2008 · External reference

RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

10.1200/jco.2009.27.15_suppl.1005 · 2009 · External reference

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

10.1016/s0140-6736(05)66544-0 · 2005 · External reference

Adjuvant chemotherapy in older women with early-stage breast cancer

10.1056/nejmoa0810266 · 2009 · External reference

CALGB 60104: adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907

10.1200/jco.2008.26.15_suppl.6542 · 2008 · External reference

A feasability study of capecitabine monotherapy for elderly patients with high risk early breast cancer

2007 · External reference

Comprehensive geriatric assessment for older patients with cancer

10.1200/jco.2007.10.6559 · 2007 · External reference

Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer

10.1200/jco.2006.10.4976 · 2007 · External reference

Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII

10.1200/jco.2000.18.7.1412 · 2000 · External reference

Docetaxel With cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735

10.1200/jco.2008.18.4028 · 2009 · External reference

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer

10.1200/jco.2006.06.5391 · 2006 · External reference

Abstract 0155

2009 · External reference

Estimating the prevalence of renal insufficiency in seniors requiring long-term care

10.1111/j.1523-1755.2004.00412.x · 2004 · External reference

Prediction of creatinine clearance from serum creatinine

10.1159/000180580 · 1976 · External reference

Using the modification of diet in renal disease (MDRD) and Cockcroft and Gault equations to estimate glomerular filtration rate (GFR) in older people

10.1093/ageing/afm121 · 2007 · External reference

Estimating renal function in older people: a comparison of three formulas

10.1093/ageing/afj041 · 2006 · External reference

Adverse drug events in ambulatory care

10.1056/nejmsa020703 · 2003 · External reference

Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay

10.1093/gerona/61.5.511 · 2006 · External reference

Understanding and preventing drug interactions in elderly patients

10.1016/j.critrevonc.2003.04.004 · 2003 · External reference

Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey

10.1001/jama.286.22.2823 · 2001 · External reference

Update on drug-related problems in the elderly

10.1016/s1543-5946(03)80014-4 · 2003 · External reference

Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial

10.1093/jnci/95.5.362 · 2003 · External reference

A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy

10.1111/j.1532-5415.2006.00789.x · 2006 · External reference

Impact of an all-oral capecitabine and vinorelbine combination regimen on functional status of elderly patients with advanced solid tumours: a multicentre pilot study of the French geriatric oncology group (GERICO)

10.1016/j.critrevonc.2009.12.003 · 2010 · External reference

A feasibility study of capecitabine monotherapy for elderly patients with high risk early breast cancer

2007 · External reference